Comparison of the Efficacy of Risperidone Made by Bakhtar Bioshimi Co. with the Risperdal Made by Janssen-Cilag Co., Belgium

The current study aimed to compare the efficacy of risperidone made by Bakhtar Bioshimi Plant with the Risperdal made by Janssen-Cilag Co. in Belgium. In the current study, 22 patients diagnosed with schizophrenia who had been referred to the private offices of some psychiatrists in Isfahan were chosen as the samples based on the DSM-IV-TR criteria and inclusion criteria. These patients were divided into Iranian and Belgian drug groups (1 and 2, respectively) with a random and double-blind method, and were examined and treated for three months with a 6-mg dose of the drug on a daily and fortnightly basis.

The PANSS scale was used to evaluate the efficacy of the drugs. The SPSS Software as well as the t-test, Mann-Whitney U test, Chi-square, covariance, Pearson’s, and Fisher’s exact statistical test were used for statistical evaluations. The mean change of PANSS scores during the evaluation was -26.1±34.12 in Group 1 and -26.9±24.25 in Group 2. In Group 1, 66.67% of the patients have shown at least a 20% reduction in PANSS total score, and 11.11% of the patients showed at least a 60% reduction in PANSS total score. In Group 2, 53.84% of the patients have shown at least a 20% reduction in PANSS total score, and 7.7% of the patients showed at least a 60% reduction in PANSS total score. There were no significant differences between the two drugs in terms of clinical and statistical efficacy, and both drugs are similar in terms of efficacy.